Research record / starter review

Tesamorelin

Growth-hormone-releasing factor analogue with a specific U.S. labelled indication

Condition-specific evidenceLast reviewed 2026-07-13

Also called

TH9507 · growth hormone-releasing factor analogue · EGRIFTA

What people ask about

Community claims

body-composition claimsvisceral-fat claimsgrowth-hormone claims

These are topics circulating in appearance, physique, or recovery communities. Listing them does not validate them.

What this record can say

Evidence snapshot

Recent controlled research in people with HIV and metabolic disease found changes in visceral and hepatic fat in that specific clinical population. FDA labelling limits the indication to HIV-associated lipodystrophy and explicitly says it is not for weight-loss management.

Safety context

Read uncertainty as information

FDA labelling includes contraindications and warnings, including effects related to IGF-1, fluid retention, glucose intolerance, hypersensitivity, and malignancy risk considerations. This record does not individualise those risks.

Tested sport

Anti-doping context

WADA's 2026 List names tesamorelin among growth-hormone-releasing hormone analogues in S2.2.4.

Regulatory scope

Context is not a universal answer

United States: EGRIFTA WR is labelled for reduction of excess abdominal fat in adults with HIV-associated lipodystrophy. The label states it is not indicated for weight-loss management.

Study-level evidence

What the individual records actually say.

Every row preserves identity and context. A related molecule, a tissue experiment, or a trial registration cannot become proof for the community claim.

Published randomised, double-blind clinical trial analysis2024

Efficacy and safety of tesamorelin in people with HIV on integrase inhibitors ↗

Russo SC, et al. PMID: 38905488.

Identity: Exact compound name: tesamorelin

Design & population: Randomised, double-blind trial analysis in 61 people with HIV, metabolic dysfunction-associated steatotic liver disease, and treatment with integrase inhibitors.

Question studied: Visceral fat, hepatic fat, and body-composition measures in a defined HIV-associated clinical context.

Record finding: The report describes significant between-group declines in visceral fat and hepatic fat in the tesamorelin group in this population.

Does not show: It does not establish an effect in people without HIV, general weight-loss management, athletic physique goals, or an individual risk-benefit decision. Clinical context and labelled indication matter.

Direct human randomised evidence — condition-specific clinical populationChecked 2026-07-13

Primary sources

Read the source, not only our summary.

U.S. product labelling / regulatoryEGRIFTA WR (tesamorelin) prescribing informationU.S. Food and Drug Administration ↗anti-doping2026 Prohibited ListWorld Anti-Doping Agency ↗bibliographic index / primary paper linksPubMedU.S. National Library of Medicine ↗